Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.48 |
| ▸ | PLAUR | Q03405 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MOK | Q9UQ07 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19429857 | 0.93 | PRMT6 (0.39) | PRMT6PLAURALDH1A1LMNAKDM4E | |
| SCHEMBL19430238 | 0.92 | PRMT6 (0.39) | PRMT6AOC3POLBMOK | |
| SCHEMBL19430397 | 0.91 | AOC3 (0.48) | PRMT6PLAURALDH1A1TSHRLMNA | |
| SCHEMBL19430109 | 0.88 | PRMT6 (0.37) | PRMT6MOK | |
| SCHEMBL19429963 | 0.88 | PRMT6 (0.37) | PRMT6AOC3MOK | |
| SCHEMBL19429860 | 0.88 | SMN1; SMN2 (0.44) | PRMT6ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL19430299 | 0.87 | PRMT6 (0.36) | PRMT6ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL19430139 | 0.86 | PRMT6 (0.41) | PRMT6AOC3MOK | |
| SCHEMBL19429853 | 0.84 | AOC3 (0.41) | PLAURALDH1A1LMNAAOC3KDM4E | |
| SCHEMBL19430232 | 0.83 | AOC3 (0.40) | AOC3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT6 4/4885PLAUR 2857/4885ALDH1A1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.